Bifidobacteria Little Helpers, Big Effects
The immune system is a complex biological system that requires many components to interact properly to protect the body from pathogens and the like. About 70 to 80 percent of immune cells are present in the intestinal lining. In addition to the gut bacteria who are already a resident, probiotics could help to modulate immune response and keep pathogens away.
The tiny intestinal microbial residents will find ideal environmental conditions there and, in turn, they leave little room for pathogenic bacteria, viruses, or fungi. The structure of the intestinal flora therefore offers you a lot of health potential.
The well-known probiotics are lactic acid bacteria and bifidobacteria. They shine with special health-promoting properties and are used to increase the numbers of good bacteria in the intestine and restore the balance of the intestinal flora.
Good to know: not all probiotics are created equal. Each bacterium has specific effects that vary from strain to strain. It is therefore important to select the appropriate probiotic for each intended efficacy for successful product development. MILEI offers the following probiotics in its product portfolio:
BB536: Multifunctional Human Bifidobacteria Strain
Bifidobacterium longum subsp. longum BB536 is one of the most established probiotic strains. It is one of Morinaga's flagships in probiotics and has a proven track record of safety and clinical efficacy1 in improving gastrointestinal, immunological, and infectious conditions, as evidenced by more than 250 scientific studies (as of March 2024).
Features:
- Human-Residential Bifidobacteria: Isolated from healthy infants
- Evidence-based Safety: Based on genomic, toxicological, and clinical studies
- Scientifically Backed: Clinically proven and confirmed by more than 250 scientific studies (as of March 2024)
- Regulatory Approved: FDA notified GRAS status for foods in 2009, FDA notified GRAS status for infant formula in 2019, ANVISA approval for supplement and conventional food products sold in Brazil in 2023, Japan FOSHU status in 1996
- Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium longum BB536 in infant and toddler foods on 11th May 2022.
M-16V: Ideal Probiotic Strain for Infant Health
Bifidobacterium breve M-16V is one of the predominant species present in the infant gut and is widely recognized for its beneficial roles in maintaining infant health2.
It has emerged as one of the best-studied clinically effective probiotic strains that exert positive effects, particularly in infants, to support healthy growth and promote well-being. More than 100 research papers habe been published (as of March 2024)
Features:
- Human-Residential Bifidobacteria: Isolated from healthy infant in 1963
- Regulatory Approved: FDA notified GRAS status for foods and infant formula in 2013
- Conducive to healthy growth, anti-infection, anti-allergy, immune development
- Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium breve M-16V in infant and toddler foods on 30th May 2016.
M-63: Probiotic Strain with Superior Potential for Infant Use
Bifidobacterium longum subsp. infantis M-63 is unique in its ability to utilize Human Milk Oligosaccharides (HMOs)3, the components are highly abundant in human breast milk.
HMOs offer no direct nutritive value for infants, but they function in shaping the infant intestinal microbiota with life-long impacts.
Features:
- Human-Residential Bifidobacteria: Isolated from healthy infant in 1963
- Regulatory Compliance: FDA notified GRAS status for foods and infant formula in 2022
- Infant Health, Digestive Health, Anti-Allergy, Mental Health
- Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium longum subsp. infantis M-63 in infant and toddler foods on 5th August 2024.
B-3: Weight Management Probiotics Strain
Bifidobacteria breve B-3 is a unique probiotic strain, developed by focusing on the relationship between gut microbiota and metabolic syndrome.
B-3 possesses an attractive effect in maintaining healthy body weight4 and ultimately improving one’s lifestyle.
Features:
- Human-Residential Bifidobacteria: Isolated from healthy infant in 2002
- Patented anti-obesity effect in many countries around the world
- Regulatory Compliance: FDA notified GRAS status for foods in 2022, the approval of Individual Recognized Registration in South Korea for its clinically demonstrated efficacy in body fat reduction in 2023.
- Healthy body fat composition and metabolic activity
All the products mentioned are:
- FSSC22000, HALAL, Kosher certified
- High storage stability
- Safety ensured through genomic, toxicological, and clinical studies
Find more information here
References
1 Wong, C. B., Odamaki, T. & Xiao, J.-Z. Beneficial effects of Bifidobacterium longum subsp. longum BB536 on human health: Modulation of gut microbiome as the principal action. J. Funct. Foods 54, (2019)
2 Wong, C. B., Iwabuchi, N. & Xiao, J.-Z. Exploring the Science behind Bifidobacterium breve M-16V in Infant Health. Nutrients 11, (2019)
3 Minami, J., Odamaki, T., Hashikura, N., Abe, F. & Xiao, J. Z. Lysozyme in breast milk is a selection factor for bifidobacterial colonisation in the infant intestine. Benef. Microbes 7, 53–60 (2016)
4 Minami, J. et al. Effects of Bifidobacterium breve B-3 on body fat reductions in pre-obese adults: A randomized, double-blind, placebo-controlled trial. Biosci. microbiota, food Heal. 1–18 (2018)
PHD Asuka Tada
Commercial Manager
+49 7561 85 402
a.tada@milei.de